PAK4 exacerbates melanoma immunosuppression by promoting exosome release.

PAK4 promotes melanoma immunosuppression by enhancing exosome release, with high PAK4 levels linked to poor anti-PD-1 therapy response in melanoma.

• Why it matters: Understanding how melanoma evades immune responses is crucial for improving immunotherapy outcomes, especially since exosomes are key immunosuppressive agents and PAK4 is associated with therapy resistance.
• What they did: The study used molecular and cellular approaches to show that PAK4 phosphorylates ANXA2 and stabilizes synaptotagmin-1, promoting exosome formation and secretion, including PD-L1-enriched exosomes, in melanoma models.
• The result: Inhibiting PAK4 reduces exosomal PD-L1 and tumor progression, suggesting that targeting PAK4 could enhance immunotherapy effectiveness and overcome resistance in melanoma patients.